Basic and clinical studies on cefpirome in respiratory infections

Hiroshi Fukuhara, Hiroaki Nakamura, Hiroshi Kaneshima, Yuei Irabu, Katnuyoshi Shimoji, Keizo Kjtsukawa, Yoshiteru Shigeno, Atsushi Saito, Shinko Taira, Isamu Nakasone, Nobuchika Kusano, Seitetsu Hokama

Research output: Contribution to journalArticlepeer-review


We performed basic and clinical studies on cefpirome (CPR), a new cephalosporin, with the following results. 1. Antimicrobial activity and concentrations in plasma and sputum. The minimum inhibitory concentrations (MICs) of CPR against a total of 307 clinically isolated strains were measured and compared with those of imipenem/cilastatin, ceftazidime, cefuzonam and ceftizoxime, using the MIC. 2000 System (Dynatech Laboratories). CPR was more potent than ceftazidime, cefuzonam and ceftizoxime against Gram positive bacteria, and than imipenem/cilastatin against Gram-negative bacteria. CPR had wide antimicrobial activity against these clinically isolated strains except methicillin resistant Staphylococcus aureus. In patients with chronic bronchitis given 2.0 g of CPR, the peak serum level of the drug was 84.2 ~ 91.0 µg/ml and the peak sputum level 0.99~1.13 µg/ml. 2. Clinical efficacy CPR (2 g/day) was given to four patients with acute exacerbation of chronic bronchitis, one with pneumonia, and one with pyothorax, for 1431 days. Clinical response was excellent in one and good in five patients, with an efficacy rate of 100%. No side effects were observed, but in clinical laboratory tests, slight and transient abnormal findings were observed in four patients.

Original languageEnglish
Pages (from-to)236-242
Number of pages7
Publication statusPublished - 1991
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology


Dive into the research topics of 'Basic and clinical studies on cefpirome in respiratory infections'. Together they form a unique fingerprint.

Cite this